Breast Cancer Clinical Trial
Official title:
The Effects of a Combined Diet and Exercise Intervention on Biomarkers Associated With Disease Recurrence After Breast Cancer Treatment: The Sheffield DEBRA Trial
| Verified date | December 2009 |
| Source | National Cancer Institute (NCI) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Unspecified |
| Study type | Interventional |
RATIONALE: Studying diet and exercise interventions in overweight and obese patients with
breast cancer may help doctors learn more about how to help patients lose weight and change
their body composition.
PURPOSE: This randomized clinical trial is studying diet and exercise to see how well it
works compared with normal care in overweight or obese women who have undergone treatment
for stage I, stage II, or stage III breast cancer.
| Status | Completed |
| Enrollment | 100 |
| Est. completion date | |
| Est. primary completion date | October 2008 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | N/A and older |
| Eligibility |
DISEASE CHARACTERISTICS: - Diagnosis of stage I, II, or III breast cancer - No metastatic breast cancer - No inoperable or active loco-regional disease - Body mass index (BMI) > 25 - Patients must have completed treatment for breast cancer within the past 3-18 months - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Female - Menopausal status not specified - Willing and able to attend supervised exercise sessions at least 3 times per week for a period of 24 weeks - Patients must be an exercise pre-contemplator, contemplator, or preparer as defined by the transtheoretical model - No physical/psychiatric impairment that would seriously impair physical mobility - No severe nausea, anorexia, or other diseases affecting health (e.g., arthritis and multiple sclerosis) - More than 3 months since prior exercise and not currently engaged in exercise (two or more times per week for at least 30 minutes per session) PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Concurrent tamoxifen, other endocrine treatments, and trastuzumab (Herceptin®) allowed - No concurrent alternative/complementary diets - No concurrent high-dose antioxidant supplement therapy - More than 4 months since prior and no concurrent hormone-replacement therapy or oral contraceptives |
Allocation: Randomized
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Sheffield Hallam University - City Campus | Sheffield | England |
| Lead Sponsor | Collaborator |
|---|---|
| Sheffield Hallam University |
United Kingdom,
Saxton JM, Daley A, Woodroofe N, Coleman R, Powers H, Mutrie N, Siddall V, Crank H. Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in wom — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Body weight | No | ||
| Primary | Body composition | No | ||
| Secondary | Pychological stress via the Perceived Stress Scale | No | ||
| Secondary | Depression via the Beck Depression Inventory II | No | ||
| Secondary | Cardiorespiratory fitness | No | ||
| Secondary | Quality of life via the FACT-G and FACT-B | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |